Nonradioactive homogeneous assays are widely used to screen for inhibitors of biomolecular interactions. To ensure optimal sensitivity for the detection of competitive inhibitors, reagent concentrations should be fixed at or below the K D of the protein-protein interaction. Accurate measurement of K D during assay development is therefore critical. Although conventional methods work well with heterogeneous assays, they are generally unsatisfactory with homogeneous systems. Here the authors describe an alternative method to determine the K D of protein-protein interactions in homogeneous assays. The method uses a rearrangement of the Cheng-Prusoff equation: IC 50 = (([K i ]/K D ) × [L]) + K i . A competitive inhibitor is titrated into the ligand-receptor binding assay at a range of ligand concentrations and IC 50 values are calculated. Plotting measured IC 50 versus concentration of ligand gives a linear plot with y-intercept (K i ) and gradient (K i /K D ). K D is the affinity constant for the ligand-receptor interaction. Here the authors use homogeneous time-resolved fluorescence (HTRF ® ) in 2 model systems (TRAIL/TRAIL receptor 4 and OX40 ligand/OX40 receptor) and demonstrate that measured K D values calculated using the linearized Cheng-Prusoff plot compare favorably with those from independent experiments. The advantages and limitations of the method are discussed. (Journal of Biomolecular Screening 2008:674-682) 
INTRODUCTION
I N RECENT YEARS THERE HAS BEEN A MOVE away from heterogeneous assay technologies in favor of simpler mix-and-read homogeneous systems in which the previously required free ligand separation steps are no longer needed. 1 Homogeneous technologies offer many advantages, such as reduced assay development and procedure time, reduced reagent usage, improved data quality, and easy implementation in high-density plate formats. Of several such technologies, one of the most widely implemented is the homogeneous time-resolved fluorescence (HTRF ® ) system from Cis Bio International (Bagnols/Cèze Cedex, France). This is one of a family of technologies based on time-resolved fluorescence resonance energy transfer (TR-FRET). At Cambridge Antibody Technology (CAT; now MedImmune Ltd.) we have found the HTRF ® system to be sensitive and robust but also highly flexible enabling successful implementation over a diverse range of screening applications in drug discovery.
The principal application of high-throughput screening (HTS) at CAT is to identify lead antibodies from the company's large (10 11 ) phage display human antibody libraries. 2 The libraries, generated using nonimmunized human donors, are designed to enable single-chain fragment variable (scFv) antibodies to be expressed on either the phage surface or as soluble scFv. 2 Typically, HTS of soluble scFv takes place only after phage display selection for antibodies binding the target molecule of interest. 2 This avoids the need to screen the libraries in their entirety and results in highly focused relatively low-throughput HTS campaigns typically of ~20,000 scFv antibodies. However, although throughput is low by small molecule screening standards, one of the specific challenges of screening biologicals at CAT is that HTS is carried out using crude unpurified bacterial lysate sample materials containing low concentrations of antibody (~50-500 nM). As a consequence of this, lead isolation HTS assay conditions must be optimized to ensure maximum sensitivity. In the case of protein-protein competition binding assays, this means that reagent concentrations must be fixed at or below the K D for the particular binding interaction. However, although there are many compelling advantages to homogeneous assays, we have found that the measurement of the K D for protein-protein interactions, although of critical importance, can be problematic with this type of assay.
Conventionally, the most commonly used methods for affinity determination have been Scatchard analysis and, more recently, nonlinear regression analysis of saturation binding data. Scatchard analysis is used in the context of radioligand binding assays and involves plotting the amount of bound radioligand divided by the amount of free radioligand in solution (y-axis) against the amount of bound radioligand (x-axis). 3 For a single-site binding interaction the plot should be linear with gradient -1/K D . Where a nonlinear Scatchard plot is observed this can be indicative of 2-site binding, cooperative binding, or other experimental artefacts. [4] [5] [6] Scatchard analysis, however, does suffer from various statistical drawbacks 7 and, as a consequence, has been largely superseded by nonlinear regression models of saturation binding that can fit data to 1 or more binding sites. These models offer the least biased statistical method to calculate K D . [8] [9] [10] Saturation binding analysis measures the specific binding of labeled ligand to the receptor at equilibrium. A plot of specific binding against concentration of labeled ligand produces a hyperbolic curve with a maximum signal or Bmax occurring when all of the available receptor sites become saturated. K D is determined from nonlinear regression curve fitting and is defined as the concentration of labeled ligand that results in 50% of the specific binding signal observed at Bmax. 10 It is noteworthy that, for this method to give a meaningful estimate of K D , the concentration of bound labeled ligand must be negligible relative to the concentration of free labeled ligand. If this is not the case, for example, with very high affinity interactions in which the true K D value may approach the physical concentration of receptor in the system, ligand depletion effects may result in an overestimate of the true K D .
In the case of homogeneous systems neither of these approaches is suitable. Scatchard analysis is not possible with nonradioactive homogeneous assays because, by definition, there is no separation of free and bound ligand. Furthermore, standard saturation binding approaches are often of limited value with homogeneous systems because the accurate estimation of Bmax can be problematic. For example, when performing saturation binding experiments with HTRF ® in an indirect format (where secondary HTRF ® detection reagents are used to indirectly detect the interaction of tagged ligand and receptor) the secondary detection reagents can become limiting before saturating concentrations of ligand are reached. The result is an effect termed the "hook effect" in which the assay signal initially increases in a titration-dependent manner at lower ligand concentrations but then reduces at higher ligand concentrations as the capacity of the secondary detection reagent is exceeded. 11 Although this situation can sometimes be addressed by increasing the concentration of secondary detection reagents, there are limits to the maximum usable concentrations of these reagents. As a result, hook effects are often unavoidable, meaning that Bmax, and consequently K D , cannot be accurately determined. This is particularly the case with lower affinity interactions in which higher ligand concentrations are required to achieve saturation.
One current method for affinity determination that alleviates the need to measure Bmax is homologous competition. 10 In this case the concentration of labeled ligand is kept constant and the affinity of the labeled ligand is derived from the IC 50 for competing unlabeled ligand according to the following equation:
Although this method avoids the need for Bmax determination, it makes the assumption that the affinities of the labeled and unlabeled ligands are the same. This is not a trivial assumption, particularly in the case of nonradioactive assays that depend on the use of either chemically labeled or biologically tagged ligands. The labeled ligand concentration used in such experiments is also highly critical in order for an accurate K D value to be obtained, and, as with conventional saturation binding, ligand depletion will complicate the analysis.
To address some of the limitations of currently available methods we have devised an alternative method of K D determination based on the principles of Cheng-Prusoff. 12 The method enables the determination of K D without the need to determine Bmax and, importantly, does not assume that the affinities of the labeled and unlabeled ligands are the same. As a consequence, we find the approach particularly valuable with homogeneous assays such as HTRF ® . The theory behind the approach is outlined below.
The Cheng-Prusoff equation defines the theoretical relationship between the measured IC 50 for a competitive inhibitor of given K i , the concentration of labeled ligand, and the K D of the ligand-receptor interaction.
where
[L] = the concentration of labeled ligand, K i = the inhibition constant, defined as the equilibrium concentration of competitive inhibitor that would occupy 50% of receptor sites if no competing labeled ligand was present, IC 50 = the concentration of competitive inhibitor that displaces 50% of the specifically bound labeled ligand, and K D = the affinity constant, defined as the equilibrium concentration of labeled ligand that occupies 50% of receptor sites in the absence of competition.
By simple rearrangement we can express the Cheng-Prusoff equation in the form: Theoretically it follows that a plot of measured IC 50 for a competitive inhibitor versus concentration of labeled ligand should be linear with y-intercept equal to K i and gradient equal to K i /K D . Experimentally the method therefore involves the measurement of competitor IC 50 at a constant receptor concentration over a range of increasing concentrations of labeled ligand. An important distinction from the homologous competition method is that the measured K D truly reflects the affinity constant for the labeled ligand binding to the receptor and the assumption of equal affinities for labeled and unlabeled ligands is not made. Indeed, the competitive inhibitor does not necessarily need to be the unlabeled ligand. However, for this method to give an accurate estimation of K D , it is essential that the assumptions inherent in the Cheng-Prusoff equation are met and this will be considered further in the discussion. We have named the method the "linearized Cheng-Prusoff method."
In this publication we demonstrate the linearized Cheng-Prusoff method in HTRF ® format focusing on the interactions of TRAIL ligand with TRAIL receptor 4 and OX40 ligand with OX40 receptor. In each case we demonstrate that measured K D values compare favorably with values determined from independent experiments and explore both the advantages and the limitations of the method.
REAGENTS AND MATERIALS

Buffer components
Phosphate-buffered saline (PBS; without Ca 2+ and Mg 2+ ;
Gibco-Invitrogen, Paisley, UK; catalog number 14190). Potassium fluoride (anhydrous; AnalaR; BDH, Poole, UK; catalog number 103444T). Bovine serum albumin (BSA; fraction V; 30% wt/vol solution;
Sigma-Aldrich, Steinheim, Germany; catalog number A9576). Marvel (dried skimmed milk; Premier International Foods, Spalding, UK).
Ligands, receptors, and associated reagents
Recombinant human TRAIL/Ap02L (Peprotech, London, UK; catalog number 310-04).
Recombinant human TRAIL was labeled with biotin, in house at CAT, using standard free amine coupling chemistry. After the labeling reaction free biotin was removed by size exclusion column separation. Biotin incorporation was determined to be 2 to 3 biotin molecules per TRAIL monomer by MALDI-TOF mass spectrometry. Recombinant All ligand, receptor, and mAb reagents were initially resuspended into PBS at concentrations ranging from 0.1 to 1.0 mg/ml and stored at -80 °C. Biotinylated TRAIL was stored in the same way but was first supplemented with 0.1% BSA.
HTRF ® ® reagents
Europium cryptate-labeled anti-human Fc (Eu-cryptateanti-Fc), europium cryptate-labeled anti-FLAG (Eu-cryptateanti-FLAG), XL 665 -labeled streptavidin (streptavidin-XL 665 ), and XL 665 -labeled anti-human Fc (anti-Fc-XL 665 ) were all obtained from Cis Bio International (Bagnols, France Ceze Cedex, France; catalog numbers 61HFCKLB, 61FG2KLB, 610SAXLB, and 61HFCXLB, respectively). HTRF ® detection reagents were resuspended and stored according to manufacturer's recommendations.
DELFIA ® ® reagents
DELFIA ® assay buffer, wash buffer, enhancer solution, Eu-N1 streptavidin, and Eu-N1 anti-human IgG were all obtained from PerkinElmer (Wellesley, MA; catalog numbers 4002-0010, 4010-0010, 4001-0010, 1244-360, and 1244-330, respectively).
Biotinylated-M2 anti-FLAG capture antibody (mouse mAb) was obtained from Sigma-Aldrich (Steinheim, Germany; catalog number F9291). 
Assay plates
METHODS
Affinity measurement by the linearized Cheng-Prusoff method using HTRF ® ®
Generic conditions
All HTRF ® competition binding experiments were performed in 40 μl of total assay volume in black 384-well Optiplate-384F assay plates using a standard assay buffer comprising of PBS supplemented with BSA (0.2%) and potassium fluoride (0.4 M; HTRF ® assay buffer). All incubations were performed at room temperature.
Determination of the affinity of biotinylated TRAIL binding to TRAILR4-Fc
Biotinylated TRAIL and unlabeled TRAIL were serially diluted into HTRF ® assay buffer and 10 μl of each dilution was added to each well of an optiplate-384F assay plate to give an 11-point duplicate 1-in-3 serial titration of unlabeled TRAIL at each concentration of biotinylated TRAIL. A solution of 2 nM TRAILR4-Fc was prepared in HTRF ® assay buffer and 10 μl was added to each well of the assay plate. For the determination of negative 665/620 nM ratio (see data analysis section), control wells containing TRAILR4-Fc and HTRF ® assay buffer only were also analyzed. Assay plates were incubated for 3 h to allow the system to reach equilibrium (previously determined in independent time course experiments). Meanwhile, secondary detection reagents were combined in HTRF ® assay buffer to give a stock solution of 3.2 nM Eucryptate-anti-Fc and 83.3 nM streptavidin-XL 665 . A total of 10 μl of the combined detection reagent solution was then added to all wells and the assay plates were incubated for a further 1.5 h before reading at 665 and 620 nM on an Envision plate reader.
Determination of the affinity of OX40R-Fc binding to OX40L-FLAG
OX40R-Fc and mAb 10541 were serially diluted into HTRF ® assay buffer and 10 μl of each dilution was added to each well of an optiplate-384F assay plate to give an 11-point duplicate 1-in-3 serial titration of mAb 10541 at each concentration of OX40R-Fc. A solution of 2 nM OX40L-FLAG was prepared in HTRF ® assay buffer and 10 μl was added to each well of the assay plate. For the determination of negative 665/620 nM ratio (see data analysis section), control wells containing OX40L-FLAG and HTRF ® assay buffer only were also analyzed. Secondary detection reagents were combined in HTRF ® assay buffer to give a stock solution of 1.73 nM Eu-cryptate-anti-FLAG and 40 nM anti-Fc-XL 665 . A total of 10 μl of the combined detection reagent solution was then added to all wells and assay plates were then incubated for 4 h to allow the system to reach equilibrium (previously determined in independent time course experiments). Plates were then read at 665 and 620 nM on an Envision plate reader.
Independent affinity measurement by standard saturation using DELFIA ® ®
Independent affinity determination for biotinylated TRAIL binding to TRAILR4-Fc
TRAILR4-Fc was diluted to 75 ng/ml (0.5 nM) in PBS and 50 μl per well was added to all wells of a Nunc-Immuno TM Maxisorp 96-well assay plate followed by incubation for 1 h. After washing 3 times with PBS the plate was blocked by addition of 200 μl per well of PBS plus 3% Marvel and incubation for a further 1 h. A duplicate 1:2 serial titration of biotinylated TRAIL was prepared in PBS plus 3% Marvel on a separate 96-well polypropylene dilution plate in the presence and absence of a constant excess concentration of unlabeled TRAIL (1 μM). After washing the assay plate 3 times with PBS, 50 μl per well of the biotinylated TRAIL titration ± excess unlabeled TRAIL was transferred to the assay plate followed by incubation for 3 h. At the end of the binding reaction the assay plate was washed 3 times with PBS followed by addition of 50 μl per well of Eu-N1 streptavidin diluted 1:1000 in DELFIA ® assay buffer. After a 1-h incubation the assay plate was washed 7 times with DELFIA ® wash buffer followed by addition of DELFIA ® enhancer solution (100 μl per well). After incubating for 5 min the assay plate was read on an Envision plate reader using a standard DELFIA ® read protocol. All incubations were performed at room temperature.
Independent affinity determination for OX40R-Fc binding to OX40L-FLAG
Biotinylated-M2 anti-FLAG capture mAb was diluted to 1 μg/ml in PBS and 50 μl per well was added to all wells of a StrepMax TM streptavidin-coated 96-well assay plate followed by incubation for 1 h. After washing 3 times with PBS, a solution of 15 ng/ml (0.5 nM) of OX40L-FLAG in PBS was added to all wells (50 μl per well) followed by incubation for 1.5 h. After washing 3 times with PBS, plates were then incubated for 1 h with 3% Marvel in PBS (200 μl per well). Meanwhile a duplicate 3-in-5 serial titration of OX40R-Fc was prepared in PBS plus 3% Marvel on a separate 96-well polypropylene dilution plate in the presence and absence of a constant excess concentration of mAb 10541 (700 nM). After washing 3 times with PBS, 50 μl per well of the OX40R-Fc titration ± excess mAb 10541 was transferred to the assay plate followed by incubation for 4 h. At the end of the binding reaction the assay plate was washed 3 times with PBS/0.01% Tween 20 followed by addition of 50 μl per well of Eu-N1 antihuman IgG diluted 1:500 in DELFIA ® assay buffer. After a 1-h incubation the assay plate was washed 7 times with DELFIA ® wash buffer followed by addition of DELFIA ® enhancer solution (100 μl per well). After incubating for 5 min the assay plate was read on an Envision plate reader using a standard DELFIA ® read protocol. All incubations were performed at room temperature.
Data analysis HTRF ® ® data
For data analysis raw 665 nM and 620 nM data were first converted to Delta F using the following equation:
Delta F = ((sample 665 nM/620 nM ratio -negative 665 nM/620 nM ratio)/ (negative 665 nM/620 nM ratio)) × 100.
In each case the negative ratio was obtained by omitting 1 of the binding partners in the ligand receptor pair. For IC 50 analysis Delta F was then converted to % specific binding taking total binding control wells to be 100% and nonspecific binding control wells to be 0% according to the following equation: Nonspecific binding was defined using an excess of either unlabeled ligand or competitive inhibitor.
DELFIA ® ® data
In DELFIA ® experiments specific binding was calculated according to the following equation:
Nonspecific binding was defined using an excess of either unlabeled ligand or competitive inhibitor as for HTRF ® assays.
Curve fitting
All curve-fitting operations were performed using Graphpad Prism Version 4. For IC 50 analysis a sigmoidal dose-response (variable slope) curve fit was used based on the standard 4parameter logistic equation. Saturation binding experiments were analyzed by curve fitting to either 1-or 2-site binding hyperbola. Figure 1 shows a typical saturation binding plot for biotinylated TRAIL binding to TRAILR4-Fc in an indirect HTRF ® assay format using the following reagent concentrations: Eu-cryptateanti-Fc (0.8 nM), TRAILR4-Fc (0.5 nM), biotinylated TRAIL (variable from 1.5 nM to 37.5 nM), and streptavidin-XL 665 (20.8 nM). Despite using a relatively high concentration of streptavidin-XL665, the data in Figure 1 clearly illustrate the hook effect in which Delta F initially increases in a titration-dependent manner but then reduces at higher biotinylated TRAIL concentrations as the streptavidin-XL665 detection reagent becomes limiting. The data highlight the fact that conventional saturation is often not satisfactory with indirect HTRF ® .
RESULTS
Affinity measurements for the interaction of biotinylated TRAIL ligand with TRAILR4-Fc
Using the same indirect HTRF ® assay configuration the affinity of biotinylated TRAIL binding to TRAILR4-Fc was determined by the linearized Cheng-Prusoff method. Here, the IC 50 for unlabeled TRAIL was measured over a range of different concentrations of biotinylated TRAIL (3.0-36.0 nM) at a constant concentration of TRAILR4-Fc (0.5 nM). Resultant unlabeled TRAIL IC 50 plots (Fig. 2a ) clearly show an expected rightward shift as the concentration of biotinylated TRAIL ligand is increased. It is evident from Figure 2a that some variation in the tops of the curves is observed (99.7 ± 2.8) as well as minor variation in Hill slopes (-1.02 ± 0.07). This may stem from minor experimental variation in total binding across the assay plates, but is insufficient to significantly compromise the analysis. Plotting unlabeled TRAIL IC 50 values versus concentration of biotinylated TRAIL (Fig. 2b) results in a linear relationship as predicted. From Figure 2b the yintercept equates to the K i for the unlabeled TRAIL ligand and the gradient equals K i /K D , where the K D is the affinity of biotinylated TRAIL ligand binding to TRAILR4-Fc. The data in Table 1 show both the unlabeled TRAIL K i and biotinylated TRAIL K D values obtained from 3 separate experiments.
Given that independent measurements for the affinity of TRAIL binding to TRAIL receptor 4 are not available in the literature, we have corroborated affinity estimates obtained from the linearized Cheng-Prusoff method with data from independent experiments. To this end standard saturation experiments were performed in DELFIA ® assay format in which the equilibrium binding of biotinylated TRAIL to immobilized TRAILR4-Fc was investigated using DELFIA ® Eu-N1 streptavidin detection. An example DELFIA ® saturation plot is shown in Figure 3 . Taking data from 2 separate DELFIA ® saturation experiments, a K D value of 2.61 ± 0.27 nM was obtained reflecting a difference of 2.1-fold relative to the HTRF ® linearized Cheng-Prusoff value of 5.54 ± 1.03 nM.
Affinity measurements for the interaction of OX40R-Fc with OX40L-FLAG
Experiments to investigate the OX40 ligand/OX40 receptor interaction were designed to measure the K D for soluble OX40R-Fc binding to OX40L-FLAG. Figure 4 shows a typical indirect HTRF ® saturation plot for soluble OX40R-Fc binding to OX40L-FLAG using the following reagent concentrations: Eu-cryptate-anti-FLAG (0.43 nM), OX40L-FLAG (0.5 nM), OX40R-Fc (variable from 0.5 nM to 12 nM), and anti-Fc-XL 665 (10.0 nM). Similar to the outcome of previous HTRF ® saturation experiments with the TRAIL system ( Fig. 1) , attempts to perform indirect HTRF ® saturation analysis with the OX40 system also result in complications due to the hook effect, which prevents a meaningful K D value to be determined. Delta F initially increases in a titration-dependent manner but then reduces at higher soluble OX40R-Fc concentrations as the anti-Fc-XL 665 detection reagent becomes limiting.
Using the same indirect HTRF ® assay configuration the affinity of soluble OX40R-Fc binding to OX40L-FLAG was determined by the linearized Cheng-Prusoff method. In this case the IC 50 for an anti-OX40L neutralizing mAb (mAb 10541) was measured over a range of different concentrations of soluble OX40R-Fc (0.5-10.0 nM) at a constant concentration of OX40L-FLAG (0.5 nM). Resultant mAb 10541 IC 50 plots (Fig. 5a) show an expected rightward shift as the concentration of soluble OX40R-Fc is increased. As with the TRAIL system it is evident from Figure 5a that some variation in the tops of the curves is observed (94.5 ± 4.4) as well as minor variation in Hill slopes (-1.07 ± 0.13). Again this is attributed to minor plate variations in total binding but is insufficient to significantly compromise the analysis. A plot of mAb 10541 IC 50 value versus concentration of soluble OX40R-Fc ( Fig. 5b) results in a linear plot. From Figure 5b the y-intercept equates to the K i for mAb 10541 and the gradient equals K i /K D , where K D corresponds to the affinity of soluble OX40R-Fc binding to OX40L-FLAG. The data in Table 2 show both mAb 10541 K i and soluble OX40R-Fc K D values obtained from 3 separate experiments.
As with the TRAIL system, affinity estimates obtained from the linearized Cheng-Prusoff method were corroborated against data from independent DELFIA ® saturation experiments. To be as consistent as possible with the Cheng-Prusoff HTRF ® assay configuration, supporting DELFIA ® saturation experiments were designed to measure the equilibrium binding of soluble OX40R-Fc to immobilized OX40L-FLAG. A biotinylated-M2 anti-FLAG 
2.08 ± 0.27 0.38 ± 0.03 5.54 ± 1.03 Note: Results from 3 separate HTRF ® K D experiments of the type presented in Figure  2a and b investigating the affinity of biotinylated TRAIL ligand binding to TRAILR4-Fc using the linearized Cheng-Prusoff method. All data are expressed as mean and standard deviation.
antibody was used to capture the OX40L-FLAG onto streptavidincoated plates and the equilibrium binding of various concentrations of soluble OX40R-Fc was then measured using an Eu-N1 anti-human IgG detection reagent. An example DELFIA ® saturation plot is shown in Figure 6a and b. Interestingly, the DELFIA ® saturation experiments show that the interaction of soluble OX40R-Fc with immobilized OX40L-FLAG is 2 sited with both a high affinity (K D = 0.29 nM ± 0.15 nM) and a secondary lower affinity interaction (K D = 46.9 ± 7.6 nM). Given that the linearized Cheng-Prusoff HTRF ® experiments were performed at OX40R-Fc concentrations well below the K D for the secondary lower affinity interaction, we believe this explains why only the higher affinity of the 2 interactions was detected in the HTRF ® experiments. Clearly the K D value derived from the Cheng-Prusoff HTRF ® experiments (0.25 ± 0.16 nM) was in very close agreement with the higher affinity of the 2 interactions measured in the DELFIA ® saturations (0.29 ± 0.15 nM).
DISCUSSION
Demonstration of the linearized Cheng-Prusoff K D method using indirect HTRF ® ®
Nonradioactive homogeneous assay technologies offer several key advantages over heterogeneous systems. In drug discovery at CAT the HTRF ® system has been widely implemented for a diverse range of protein-protein interaction-based HTS. A key stage in the assay development process is the determination of the K D for the particular protein-protein interaction. This is important in lead isolation HTS in which we aim to fix reagent concentrations at or below K D to ensure optimum sensitivity to detect inhibitors. Equally, K D measurement is also important in the development of assays for lead optimization screening. Here we may need to fix reagent concentrations substantially above K D to enhance discrimination between inhibitors of low K i . However, when using existing methods, the measurement of K D is not straightforward in homogeneous assay systems as described in the introductory section.
To address these limitations we have developed an alternative method based on Cheng-Prusoff principles. 12 The method depends on measuring competitor IC 50 values over a range of concentrations of tagged ligand or receptor at a constant concentration of the opposite member in the binding pair. Experiments can be configured with either a constant concentration of tagged receptor and variable concentration of tagged ligand or with a constant concentration of tagged ligand and variable concentration of tagged receptor. For clarity the constant component in the system will henceforth be referred to as the "target" and the variable component as the "tracer." Importantly, the competitor in the system must always compete with the tracer for binding to the target. Irrespective of orientation, a subsequent plot of competitor IC 50 versus concentration of tracer gives a y-intercept equal to the competitor K i and a gradient equal to K i /K D , where K D is the affinity of tracer binding to target.
Here we have demonstrated the method using HTRF ® focusing on 2 model ligand receptor systems from the TNF superfamily. First we investigated the affinity of biotinylated TRAIL (tracer) binding to TRAILR4-Fc (target) using unlabeled TRAIL as competitor. The measured K D from the linearized Cheng-Prusoff method (5.54 ± 1.03 nM) was 2.1 fold higher than the value obtained from saturation binding in DELFIA ® format (2.61 ± 0.27 nM). In principle this could reflect a level of bias in either analysis method and, although nonlinear regression methods are generally favored, the potential for bias in both linear and nonlinear regression has been a subject of debate in the literature. 8, 13 We also investigated the affinity for OX40R-Fc (tracer) binding to OX40L-FLAG (target) using an anti-OX40L neutralizing mAb as competitor. Here the results derived from the linearized Cheng-Prusoff method (K D = 0.25 ± 0.16 nM) agreed closely with those derived from DELFIA ® saturation experiments (K D = 0.29 ± 0.15 nM), although a secondary lower affinity interaction (K D = 46.9 ± 7.6 nM) was also detected at the higher reagent concentrations used in the DELFIA ® experiments. For reasons outlined in the results section, it is valid to compare the linearized Cheng-Prusoff K D against the K D for the higher affinity of the 2 interactions measured in DELFIA ® saturation, and the close agreement between these values helps to validate the method. It is likely that the 2site binding measured in DELFIA ® may reflect differential affinities for the interactions of monomer and trimer forms of OX40L with the receptor as has been suggested in the literature from studies investigating murine OX40L. 14 
Assumptions and limitations in the linearized Cheng-Prusoff method
Having evaluated results from the linearized Cheng-Prusoff method against data from independent experiments, we believe the method provides a solution to the problem of determining K D using HTRF ® . Although the potential for bias cannot be ruled out completely, the method is sufficiently accurate to be of value in drug discovery assay development. However, given that the method depends intrinsically upon predictions from the Cheng-Prusoff equation, 12 to get the best outcome from the method, consideration should be given to the experimental conditions used to ensure that the assumptions inherent in the equation are met. These assumptions are discussed below. 1) The system is at equilibrium. This is essential because both K i and K D are defined under equilibrium conditions. 2) There is a single site of binding for both tracer and competitive inhibitor. This is also important, although in cases where 2 interactions of widely different affinities are apparent it may be possible to tailor experimental conditions to focus on just 1 of the 2 interactions, as with the OX40L HTRF ® experiments. 3) Binding is reversible and noncooperative. The Cheng-Prusoff equation assumes the law of mass action, and consequently the linearized Cheng-Prusoff method, should be applied only to the analysis of reversible noncooperative interactions. 4) There is no significant depletion of either tracer or competitor on binding to the target, meaning that free and total concentrations are effectively equal in each case. This final assumption is typically the most difficult to satisfy. Complications due to depletion of tracer are more acute with higher affinity interactions, particularly where the K D for the tracer binding to the target approaches the target concentration in the system. Here the free and total tracer concentrations will differ and lead to error in any subsequent analyses using total tracer concentration as a surrogate measure of free concentration. Because of the difficulty in quantifying tracer depletion in nonradioactive systems, the most effective strategy is to reduce the target concentration to a concentration below the K D for the particular interaction. Similarly, in the case of competitor depletion, problems can arise if the K i for the competitor is close to the concentration of target in the system. Significant competitor depletion would typically result in steeper inhibition curves and, in the context of the present study, would be reflected in a nonlinear plot of IC 50 versus concentration of tracer. Again, reducing the concentration of target is an effective strategy to control this, although, in the case of competitor depletion, the use of a competitor with a higher K i is also an option. It should be noted, however, that both homologous competition and saturation binding approaches also depend on the absence of depletion effects, so this issue is no more of a consideration with the linearized Cheng-Prusoff approach than is the case with existing methods.
Practical approaches to minimize target concentrations with HTRF ® ®
The lower limit of target concentration is largely dictated by the absolute sensitivity of the assay technology used. For the measurement of very high affinity interactions the inherent sensitivity of the particular assay technology is therefore relevant. However, it is equally relevant to ensure that the assay conditions are optimized to ensure the maximum potential sensitivity of the particular assay technology. The optimization of assay sensitivity is relevant not only to the measurement of high affinity interactions but also in ensuring reagent concentrations can be fixed at or below K D in the final HTS. Typically, for indirect HTRF ® assays in a 40-μl assay volume, the minimum target concentration achievable is in the area of 0.25 to 0.5 nM. However, from recent work we have identified several potential factors that may result in improved sensitivity, thus enabling reduced target concentrations to be used. First, we suspect that the strategy of direct europium-cryptate labeling of the target can result in enhanced sensitivity relative to indirect HTRF ® detection approaches. Clearly, consideration must be given to whether the particular target could be adversely affected by direct europium-cryptate labeling. This will depend on the coupling chemistry used and the position of potential labeling sites within the molecule. An alternative approach to realize sensitivity gains may be to consider different forms of europium. For example, it is claimed that the new europium chelate nanoparticles from ProxiScreen can result in sensitivity gains of 10-to 100-fold in TR-FRET assays. This is something we plan to evaluate. We are also interested in evaluating the potential benefits of using direct europium-cryptate labeling in conjunction with direct D2 labeling. D2 is a new alternative to XL 665 that may have advantages for use in direct labeled assays because of its relative small size. Another area in which potential exists to improve HTRF ® assay sensitivity includes further miniaturization of assay volume and the use of low volume 384-well plates. The experiments in this publication have been performed with 40-μl assay volume in standard-depth 384F optiplates. However, preliminary findings suggest moderate sensitivity gains may be achievable using 20-μl assay volume and low volume 384-well plates. Collectively, the above strategies should enable reduced target concentrations to be used, thus minimizing effects due to depletion. This will facilitate the measurement of higher affinity interactions and enable appropriate final HTS conditions to be adopted.
CONCLUSIONS
Ongoing investigations will no doubt result in refinements to the linearized Cheng-Prusoff method thereby extending our capabilities in the area of K D analysis using HTRF ® . However, we have successfully implemented the approach and now use the method routinely in the development of HTS assays in both lead isolation and lead optimization. Provided that due consideration is given to the assumptions and limitations inherent within the technique, the method can provide a valuable tool that can be used to investigate biomolecular interactions using HTRF ® . Furthermore, we believe the method is not limited to HTRF ® and has generic application in the study of protein-protein interactions in homogeneous assays.
